-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
HCW Biologics Inc. (NASDAQ:HCWB) Sees Large Growth in Short Interest
HCW Biologics Inc. (NASDAQ:HCWB) Sees Large Growth in Short Interest
HCW Biologics Inc. (NASDAQ:HCWB – Get Rating) was the recipient of a significant increase in short interest in November. As of November 30th, there was short interest totalling 26,200 shares, an increase of 84.5% from the November 15th total of 14,200 shares. Based on an average daily trading volume, of 21,100 shares, the short-interest ratio is currently 1.2 days. Currently, 0.2% of the shares of the stock are sold short.
Wall Street Analyst Weigh In
Separately, Jonestrading began coverage on shares of HCW Biologics in a research note on Monday, November 7th. They issued a "buy" rating and a $8.00 price target on the stock.
Get HCW Biologics alerts:Institutional Investors Weigh In On HCW Biologics
Several hedge funds and other institutional investors have recently bought and sold shares of HCWB. HighTower Advisors LLC increased its position in HCW Biologics by 2,056.0% during the first quarter. HighTower Advisors LLC now owns 215,598 shares of the company's stock worth $588,000 after purchasing an additional 205,598 shares during the last quarter. BlackRock Inc. increased its position in HCW Biologics by 136.8% during the first quarter. BlackRock Inc. now owns 39,583 shares of the company's stock worth $108,000 after purchasing an additional 22,869 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in HCW Biologics by 9.8% during the third quarter. Vanguard Group Inc. now owns 95,392 shares of the company's stock worth $218,000 after purchasing an additional 8,494 shares during the last quarter. 1.59% of the stock is currently owned by institutional investors and hedge funds.
HCW Biologics Price Performance
HCW Biologics stock traded up $0.17 during midday trading on Thursday, hitting $2.10. 67,140 shares of the stock were exchanged, compared to its average volume of 33,825. HCW Biologics has a fifty-two week low of $1.76 and a fifty-two week high of $3.32. The stock's 50-day simple moving average is $2.18 and its 200 day simple moving average is $2.28. The company has a debt-to-equity ratio of 0.15, a current ratio of 12.52 and a quick ratio of 12.52.HCW Biologics Company Profile
(Get Rating)
HCW Biologics Inc, a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases.
See Also
- Get a free copy of the StockNews.com research report on HCW Biologics (HCWB)
- This is no Time to Buy Lennar but the Time is Coming
- Game-Changing News For Mullen Automotive
- Inflation and the Energy Crisis are Two Freight Trains on a Collision Course – Here's How to Prepare
- Is Enterprise Products Partners Fairly Valued?
- Will WhatsApp Partnership Boost MercadoLibre's Earnings?
Receive News & Ratings for HCW Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCW Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
HCW Biologics Inc. (NASDAQ:HCWB – Get Rating) was the recipient of a significant increase in short interest in November. As of November 30th, there was short interest totalling 26,200 shares, an increase of 84.5% from the November 15th total of 14,200 shares. Based on an average daily trading volume, of 21,100 shares, the short-interest ratio is currently 1.2 days. Currently, 0.2% of the shares of the stock are sold short.
新华生物股份有限公司(纳斯达克代码：HCWB-GET评级)是11月份空头股数大幅增长的接受者。截至11月30日，空头股数共有26,200股，比11月15日的14,200股增长了84.5%。以日均成交量2.11万股计算，目前短息比为1.2天。目前，该股0.2%的股份被卖空。
Wall Street Analyst Weigh In
华尔街分析师也加入进来
Separately, Jonestrading began coverage on shares of HCW Biologics in a research note on Monday, November 7th. They issued a "buy" rating and a $8.00 price target on the stock.
另外，Jones Trading在11月7日星期一的一份研究报告中开始报道HCW Biologics的股票。他们对该股的评级为“买入”，目标价为8.00美元。
Institutional Investors Weigh In On HCW Biologics
机构投资者看好HCW生物制品
Several hedge funds and other institutional investors have recently bought and sold shares of HCWB. HighTower Advisors LLC increased its position in HCW Biologics by 2,056.0% during the first quarter. HighTower Advisors LLC now owns 215,598 shares of the company's stock worth $588,000 after purchasing an additional 205,598 shares during the last quarter. BlackRock Inc. increased its position in HCW Biologics by 136.8% during the first quarter. BlackRock Inc. now owns 39,583 shares of the company's stock worth $108,000 after purchasing an additional 22,869 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in HCW Biologics by 9.8% during the third quarter. Vanguard Group Inc. now owns 95,392 shares of the company's stock worth $218,000 after purchasing an additional 8,494 shares during the last quarter. 1.59% of the stock is currently owned by institutional investors and hedge funds.
几家对冲基金和其他机构投资者最近买卖了华侨银行的股票。HighTower Advisors LLC在第一季度将其在HCW Biologics的地位增加了2056.0%。HighTower Advisors LLC在上个季度额外购买了205,598股后，现在拥有215,598股该公司股票，价值58.8万美元。贝莱德股份有限公司在第一季度增持了136.8%的惠康生物股份。贝莱德股份有限公司在上个季度增持了22,869股后，现在持有39,583股该公司股票，价值108,000美元。最后，先锋集团在第三季度将其在HCW Biologics的头寸增加了9.8%。先锋集团(Vanguard Group Inc.)在上个季度增持了8,494股后，目前持有95,392股该公司股票，价值21.8万美元。该股目前由机构投资者和对冲基金持有1.59%。
HCW Biologics Price Performance
HCW生物制品性价比
HCW Biologics Company Profile
HCW生物制品公司简介
(Get Rating)
(获取评级)
HCW Biologics Inc, a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases.
HCW生物制药公司是一家临床前阶段的生物制药公司，专注于发现和开发针对慢性、低级别炎症和年龄相关疾病的新型免疫疗法。该公司的主导产品包括HCW9218，这是一种可注射免疫疗法，用于治疗胰腺癌、卵巢癌、乳腺癌、前列腺癌和结直肠癌以及肺纤维化患者；以及HCW9302，用于治疗自身免疫性疾病，如斑秃和代谢性疾病。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on HCW Biologics (HCWB)
- This is no Time to Buy Lennar but the Time is Coming
- Game-Changing News For Mullen Automotive
- Inflation and the Energy Crisis are Two Freight Trains on a Collision Course – Here's How to Prepare
- Is Enterprise Products Partners Fairly Valued?
- Will WhatsApp Partnership Boost MercadoLibre's Earnings?
- 免费获取StockNews.com关于HCW生物制品的研究报告(HCWB)
- 现在不是购买Lennar的时候，但时机即将到来
- 马伦汽车公司改变游戏规则的消息
- 通货膨胀和能源危机是两列相撞的货运列车--以下是如何做好准备的
- 企业产品合作伙伴是否得到公平评价？
- WhatsApp合作伙伴关系是否会提振MercadoLibre的收益？
Receive News & Ratings for HCW Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCW Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《HCW生物制品日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对HCW Biologics和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧